Interactive Brokers Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

YMI Read Me First: (sorry DEW, The Ihub

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ThomasS Member Profile
Followed By 12
Posts 2,364
Boards Moderated 0
Alias Born 05/05/05
160x600 placeholder
ThomasS   Friday, 06/24/05 11:14:03 PM
Re: A deleted message
Post # of 214403 
YMI Read Me First: (sorry DEW, The Ihub server keeps going down while I edit)

Rodman Webcast and 44-slide presentation, 5/2005 (EXCELLENT MUST READ/LISTEN!)

YMI 13 May 2005 3rd QTR commentary from management (including cash burn thru 2006)
As at March 31, 2005 the Company had cash and short-term deposits totaling $31,081,073 and current liabilities of $1,018,028 compared to $20,387,858 and $1,163,711 respectively at June 30, 2004. The Company anticipates that the current cash reserves will be sufficient to support its current development program through the end of the 2006 fiscal year.

5/19/05 ASCO Tesmilifene results:
A total of 305 patients were enrolled in the MA.19 trial. Of the 191 patients in whom cancer metastasized or recurred within 36 months from original diagnosis to trial entry, patients in the arm combining doxorubicin with tesmilifene had a median survival of 29.7 months compared to 12.2 months for patients on doxorubicin alone, a 143% improvement in overall survival (p(equal sign)0.0016). The patient population of 305 was divided into tertiles of patients who had a disease-free interval (DFI) of greater than 36 months, 6 to 36 months and less than 6 months. The DFI group greater than 36 months demonstrated no benefit from the additional tesmilifene while the combined groups of less than 36 months DFI demonstrated the significant 143% difference in this unplanned, post-hoc analysis.

Twist Interview excerpt with David Allan, CEO 1/10/2005
"Tesmilifene acts by potentiating all known current chemotherapies. On its own it is somewhat cytotoxic, but its real effect is enhancing the activity of other cytotoxic drugs. In the metastatic setting, very little has happened in terms of increasing survival of patients with recurrent or metastatic disease in the last 50 years. In metastatic breast cancer, the only evident increase in survival in that period of time was demonstrated by Herceptin, which produces about a 24% increase in survival and works in about a third of the women with metastatic breast cancer because of the pre-requisite to over express the Her-2 gene in order for Herceptin to be effective. Tesmilifene, in its first Phase III trial, demonstrated a 140% increase in overall survival time in women with metastatic breast cancer ' significantly more potent apparently than Herceptin ' in a specific patient population in that trial. Under the special protocol assessment in the current clinical trial, the FDA requires YM to demonstrate a 33% benefit in order to register the drug in the same specific patient population as the first trial. So there is a great deal hanging on this trial, but a considerable amount of evidence the trial is likely to have a positive outcome. The strategies for tesmilifene are, first of all, to get the registration in the current indications and then, probably, to expand the drug into hormone-refractory prostate cancer where we already have significant clinical data from a completed US trial and then eventually into lung cancer, lymphoma and, ultimately, into the adjuvant setting in breast cancer. So the drug, if it is successful in this trial, could very well turn out to be a drug of considerable importance in the cancer landscape."

Feb 08 2005 Bioscience World interview with David Allan (courtesy RANDY): “The instant we license a drug in we start thinking about who might want to buy it from us,” says YM chairman and CEO David Allan. YM understands that sometimes plans unexpectedly change, and therefore, approaches commercialization on a drug-to-drug basis, Allan says. Typically, the company looks to have out-partnering deals by the Phase II stage of clinical development. “The reason that tesmilifene and TheraCIM are still, by great good fortune, in our portfolio and not partnered, is just dumb luck,” he says.

YMI Pipeline minus DELEX:

DELEX: news link and conference call link:

12/22/2004 Merriman notes and $8-$12 target (Kate Winkler?)

13:47 YMI YM BioSciences: Color on TheraCIM data - Merriman (2.61 +0.11)
Merriman notes that yesterday YMI announced preliminary results from a randomized phase II trial conducted by its licensor in Cuba, and says TheraCIM may be better than equivalent to Erbitux. Notably, there was no evidence of skin rash, which has been seen with all other EGF receptor-blocking agents and has previously been assumed to be inseparable from efficacy. While survival data will be needed in order to compare these impressive tumor response results with those of Erbitux radiation therapy in head and neck cancer, firm believes that increasing visibility of the co's valuable pipeline could catalyze gains in the stock over the next 12-18 months toward $8-$12, a valuation more closely in-line with peers.

13 May 2005 Stanford Research Note:

10:04 YMI YM BioSciences started with a Buy at Stanford; tgt $6 (2.15 -0.04)
Stanford initiates YMI with a Buy and $6 tgt, saying few biotech co's offer as rich a pipeline as YMI, let alone with a mkt cap of just ~$100 mln. Firm believes that investors are not fully aware of the potential of Tesmilifene, and they say TheraCIM offers several advantages over Erbitux and ABX-EGF, including no anaphylaxis.

"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist